Image

Observational Study of Double Cord Blood Transplant

Observational Study of Double Cord Blood Transplant

Recruiting
19 years and older
All
Phase N/A

Powered by AI

Overview

The efficacy and safety of non-myeloablative and myeloablative preconditioning followed by dual-unit umbilical cord blood transplantation from unrelated donors in adult patients with malignant hematologic diseases eligible for allogeneic hematopoietic stem cell transplantation are evaluated through prospective observation and analysis of actual clinical data collection

Eligibility

Inclusion Criteria:

  • (1) Aged 19 and older (2) Patients scheduled for umbilical cord blood transplantation as a primary allogeneic hematopoietic stem cell transplantation for the treatment of the following hematologic diseases:
    • Acute leukemia (myeloid/lymphoid/mixed lineage) planned for transplantation for treatment purposes
      • Myelodysplastic syndromes planned for transplantation for treatment purposes ③ Chronic leukemia (myeloid/lymphoid/monocytic) and myeloproliferative neoplasms planned for transplantation for treatment purposes ④ Malignant lymphomas, multiple myeloma planned for transplantation for treatment purposes ⑤ Other malignant hematologic malignancies planned for transplantation for treatment purposes ⑥ Planned for transplantation for the treatment of bone marrow failure diseases, including aplastic anemia (3) If all contents of the consent form are understood and consented to in writing.

Exclusion Criteria:

  • (1) Patients with a history of allogeneic hematopoietic stem cell transplantation or those undergoing transplantation for the treatment of engraftment failure (secondary allogeneic hematopoietic stem cell transplantation is an exclusion criterion; however, patients eligible for registration include those undergoing their first allogeneic stem cell transplantation following an autologous stem cell transplantation).

    (2) Patients with severe, uncontrolled infections or severe cardiopulmonary dysfunction, as judged by the investigator.

    (3) Patients with an ECOG Performance Status (PS) greater than 3 or those receiving mechanical ventilation in the intensive care unit.

    (4) Patients who do not consent to participate in the study or those deemed unsuitable for sincere participation by the attending physician.

Study details
    Adult Double Unit Cord Blood Transplant

NCT06712108

Seoul National University Hospital

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.